Literature DB >> 11124846

Prevalence and significance of hepatitis B virus (HBV) pre-S mutants in serum and liver at different replicative stages of chronic HBV infection.

Y F Fan1, C C Lu, W C Chen, W J Yao, H C Wang, T T Chang, H Y Lei, A L Shiau, I J Su.   

Abstract

Several types of naturally occurring pre-S mutants in sera or liver tissues in patients with chronic hepatitis B virus (HBV) infection have been identified. To clarify the prevalence and significance of emergence of pre-S mutants, 140 sera and 18 resected livers from patients with HBV were studied. Replicative status was designated as high, intermediate, and low based on the HBV-DNA levels in serum or the expression of HBV antigens in liver. In vitro transfection and Western blot analysis were performed to characterize expression and secretion of HBsAg by the mutant constructs. Five major types (I to V) of pre-S deletion mutants in serum and liver and 2 types (VI and VII) in liver were identified. Pre-S mutant was 6.4% at high replicative phase, 13% at intermediate, and 37.5% at low or nonreplicative phases in serum. In livers, the same tendency existed: pre-S2 deletion mutants emerged and prevailed at a low replicative phase in hepatocytes that expressed a novel marginal pattern of HBsAg and usually clustered in groups. The deletion sequence of pre-S2 region coincides with human leukocyte antigen-restricted T- and B-cell epitopes. In vitro HBsAg was retained in the hepatocytes and synthesis and secretion of major surface antigen decreased for most of the pre-S mutants. Pre-S mutants prevailed with evolution of chronic HBV, probably under immune pressure. Emergence of pre-S mutants may account for the life-long persistence and discrepancy of HBsAg in serum and liver in HBV and may confer growth advantage in view of the clustering proliferation of hepatocytes harboring pre-S2 mutant.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11124846     DOI: 10.1053/jhep.2001.21163

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  59 in total

1.  Current status of antiviral therapy for hepatitis B.

Authors:  Daryl T-Y Lau; Wissam Bleibel
Journal:  Therap Adv Gastroenterol       Date:  2008-07       Impact factor: 4.409

Review 2.  Genotypes and viral variants in chronic hepatitis B: A review of epidemiology and clinical relevance.

Authors:  Catherine Mn Croagh; Paul V Desmond; Sally J Bell
Journal:  World J Hepatol       Date:  2015-03-27

3.  In vivo transmission and dynamics of deleted genomes after experimental infection of woodchuck hepatitis B virus in adult animals.

Authors:  Valentina La Sorsa; Claudio Argentini; Roberto Bruni; Umberta Villano; Roberto Giuseppetti; Maria Rapicetta
Journal:  Virus Genes       Date:  2002-10       Impact factor: 2.332

4.  Zinc-dependent interaction between JAB1 and pre-S2 mutant large surface antigen of hepatitis B virus and its implications for viral hepatocarcinogenesis.

Authors:  Jye-Lin Hsu; Woei-Jer Chuang; Ih-Jen Su; Wen-Jun Gui; Yu-Ying Chang; Yun-Ping Lee; Yu-Lin Ai; David T Chuang; Wenya Huang
Journal:  J Virol       Date:  2013-09-18       Impact factor: 5.103

Review 5.  The evolution and clinical impact of hepatitis B virus genome diversity.

Authors:  Peter A Revill; Thomas Tu; Hans J Netter; Lilly K W Yuen; Stephen A Locarnini; Margaret Littlejohn
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2020-05-28       Impact factor: 46.802

6.  High prevalence of hepatitis B virus pre-s mutant in countries where it is endemic and its relationship with genotype and chronicity.

Authors:  Tran Thien-Tuan Huy; Hiroshi Ushijima; Khin Maung Win; Pairoj Luengrojanakul; Pradeep Krishna Shrestha; Zhao-Hua Zhong; Andrei V Smirnov; Teresa Casanovas Taltavull; Tetsutaro Sata; Kenji Abe
Journal:  J Clin Microbiol       Date:  2003-12       Impact factor: 5.948

7.  A pre-S gene chip to detect pre-S deletions in hepatitis B virus large surface antigen as a predictive marker for hepatoma risk in chronic hepatitis B virus carriers.

Authors:  Fan-Ching Shen; Ih-Jen Su; Han-Chieh Wu; Yi-Hsuan Hsieh; Wei-Jen Yao; Kung-Chia Young; Tsung-Chuan Chang; Hui-Chuan Hsieh; Han-Ni Tsai; Wenya Huang
Journal:  J Biomed Sci       Date:  2009-09-15       Impact factor: 8.410

8.  Overlapping gene mutations of hepatitis B virus in a chronic hepatitis B patient with hepatitis B surface antigen loss during lamivudine therapy.

Authors:  Sun Young Lee; Moon Seok Choi; Dongho Lee; Joon Hyoek Lee; Kwang Cheol Koh; Seung Woon Paik; Byung Chul Yoo
Journal:  J Korean Med Sci       Date:  2005-06       Impact factor: 2.153

9.  Hepatitis B viral surface mutations in patients with adefovir resistant chronic hepatitis B with A181T/V polymerase mutations.

Authors:  Jeong Han Kim; Young Kul Jung; Moon Kyung Joo; Ji Hoon Kim; Hyung Joon Yim; Jong-Jae Park; Jae Seon Kim; Young-Tae Bak; Jong Eun Yeon; Kwan Soo Byun
Journal:  J Korean Med Sci       Date:  2009-01-19       Impact factor: 2.153

10.  Hepatitis B virus pre-S deletion mutations are a risk factor for hepatocellular carcinoma: a matched nested case-control study.

Authors:  Zhong-Liao Fang; Caroline A Sabin; Bai-Qing Dong; Shao-Chao Wei; Qin-Yan Chen; Kong-Xiong Fang; Jin-Ye Yang; Jian Huang; Xue-Yan Wang; Tim J Harrison
Journal:  J Gen Virol       Date:  2008-11       Impact factor: 3.891

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.